Moreover, in silico analysis of the data from Genevesigator platform reveled that PAK1 and PAK2 (but not PAK3, PAK4, PAK5, etc.)are highly expressed in CML indicating a privileged role of PAK1 and/or PAK2 in the pathogenesis of BCR-ABL1 positive diseases [43]. This evidence concerns the gene PAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.